EMA Authorised: Ebymect (dapagliflozin propanediol monohydrate;metformin hydrochloride) — AstraZeneca AB

View source ↗

Summary

The EMA authorised Ebymect, a fixed-dose combination of dapagliflozin propanediol monohydrate and metformin hydrochloride, for Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Ebymect (dapagliflozin propanediol monohydrate; metformin hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: AstraZeneca AB. Decision date: 12/03/2026